We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagUS

18889881171

MSFT 416.99 -0.2798% AAPL 236.12 0.4766% NVDA 141.89 2.8188% GOOGL 163.9 0.2937% GOOG 165.62 0.3453% AMZN 188.49 -0.2646% META 572.8 -0.6366% AVGO 179.26 -0.3502% TSLA 217.715 -1.3525% TSM 201.3996 0.3086% LLY 907.515 -1.1389% V 287.48 -1.0804% JPM 223.49 -0.8342% UNH 572.61 0.5267% NVO 117.1969 -0.7563% WMT 81.0075 -0.372% LVMUY 132.13 -2.3429% XOM 120.405 0.3291% LVMHF 664.5 -1.9483% MA 515.685 -0.1269%

TC BioPharm Holdings PLC

Healthcare US TCBP

2.3501USD
-2.7099(53.56%)

Last update at 2024-10-21T18:53:00Z

Day Range

1.895.04
LowHigh

52 Week Range

0.8519.60
LowHigh

Fundamentals

  • Previous Close 5.06
  • Market Cap5.64M
  • Volume1992897
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.92370M
  • Revenue TTM2.86M
  • Revenue Per Share TTM29.64
  • Gross Profit TTM 3.84M
  • Diluted EPS TTM-19.51

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -3.10971M -14.98347M -6.62984M -6.89405M
Minority interest - - - -
Net income -1.38971M -13.57592M -5.45792M -6.06798M
Selling general administrative 8.32M 3.11M 2.21M 3.01M
Selling and marketing expenses - - - -
Gross profit 3.84M 1.98M 1.98M 3.43M
Reconciled depreciation 0.97M 1.03M 1.08M 0.90M
Ebit -12.05925M -7.28061M -6.33778M -6.61864M
Ebitda -11.09308M -6.25555M -5.26257M -5.71417M
Depreciation and amortization 0.97M 1.03M 1.08M 0.90M
Non operating income net other - - - -
Operating income -12.05925M -7.28061M -6.33778M -6.61864M
Other operating expenses 15.77M 9.26M 8.32M 10.07M
Interest expense 6.99M 3.44M 0.29M 0.28M
Tax provision -1.72000M -1.40754M -1.17193M -0.82607M
Interest income 0.00221M 0.00003M 0.00103M 0.02M
Net interest income -6.99221M -3.43852M -0.29103M -0.25351M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -1.72000M -1.40754M -1.17193M -0.82607M
Total revenue 3.84M 1.98M 1.98M 3.43M
Total operating expenses 15.77M 9.26M 8.32M 10.07M
Cost of revenue - - - -
Total other income expense net 8.95M -7.70286M -0.29206M -0.27541M
Discontinued operations - - - -
Net income from continuing ops -1.38971M -13.57592M -5.45792M -6.06798M
Net income applicable to common shares -1.38971M -13.57592M -5.45792M -6.06798M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 8.93M 10.95M 8.02M 7.27M 10.14M
Intangible assets 0.62M 0.55M 0.48M 0.42M 0.31M
Earning assets - - - - -
Other current assets 3.24M - 0.81M 0.23M 0.24M
Total liab 6.25M 10.98M 24.58M 10.61M 12.68M
Total stockholder equity 2.69M -0.02568M -16.55905M -3.34707M -2.53941M
Deferred long term liab - - - - -
Other current liab 0.01M 7.30M 9.61M 1.13M 0.81M
Common stock 0.00206M 0.40M 0.20M 1.78M 1.78M
Capital stock 0.00206M 0.40M 0.20M 1.78M 1.78M
Retained earnings -38.83729M -33.73174M -33.46528M -19.88936M -15.41615M
Other liab - - 1.87M 3.84M 5.77M
Good will - - - - -
Other assets - - - - -
Cash 2.46M 4.81M 1.57M 0.75M 0.96M
Cash and equivalents - - - - -
Total current liabilities 4.75M 9.16M 20.58M 4.19M 3.88M
Current deferred revenue 2.58M - 1.98M 1.98M 2.03M
Net debt -0.66145M -2.01409M 8.14M 2.28M 2.48M
Short term debt 0.31M 0.98M 7.57M 0.44M 0.41M
Short long term debt - 0.65M 6.81M - -
Short long term debt total 1.80M 2.79M 9.71M 3.03M 3.44M
Other stockholder equity 41.52M 16.60M 16.71M 14.76M 11.10M
Property plant equipment - 2.95M 3.68M 4.63M 5.61M
Total current assets 5.70M 7.45M 3.86M 2.22M 4.22M
Long term investments - - - - -
Net tangible assets - -0.57869M -17.04263M -3.77091M -2.84504M
Short term investments - - - - -
Net receivables 1.23M 1.80M 1.48M 1.24M 3.02M
Long term debt - - - - -
Inventory -1.23082M - - - -
Accounts payable 1.85M 0.88M 1.42M 0.64M 0.63M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M 16.71M 16.71M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 3.23M 3.50M 4.17M 5.05M 5.92M
Capital lease obligations 1.80M 2.14M 2.90M 3.03M 3.44M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.31020M -0.14322M -0.20499M -2.19660M
Change to liabilities -5.78909M 0.36M 0.33M -0.04161M
Total cashflows from investing activities -0.31020M -0.14322M -0.20499M -2.19660M
Net borrowings -3.37636M 6.26M -0.41527M 0.14M
Total cash from financing activities 17.89M 6.53M 3.43M 3.27M
Change to operating activities - - -1.97866M -2.03075M
Net income -3.10971M -14.98347M -6.62984M -6.89405M
Change in cash 3.24M 0.82M -0.20848M -5.71448M
Begin period cash flow 1.57M 0.75M 0.96M 6.67M
End period cash flow 4.81M 1.57M 0.75M 0.96M
Total cash from operating activities -14.53015M -5.58102M -3.43187M -6.72962M
Issuance of capital stock 3.37M 0.29M 3.90M 3.14M
Depreciation 0.97M 1.03M 1.08M 0.90M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables -0.03750M -0.59162M 1.73M 0.26M
Sale purchase of stock - - - -
Other cashflows from financing activities 17.92M 6.36M -0.05327M 0.32M
Change to netincome -8.28002M 7.20M 0.87M 0.25M
Capital expenditures 0.37M 0.14M 0.20M 2.20M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital -5.82659M -0.23208M 0.08M -1.81431M
Stock based compensation 1.12M 0.00000M 0.80M 0.84M
Other non cash items -7.68327M 8.61M 0.29M 0.25M
Free cash flow -14.89534M -5.72425M -3.63686M -8.92623M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TCBP
TC BioPharm Holdings PLC		 -2.7099 53.56% 2.35 - - 0.51 1.53 1.83 -0.6869
NVO
Novo Nordisk A/S		 -0.8931 0.76% 117.20 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 117.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.23 0.67% 482.30 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -17.68 1.78% 973.00 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

TC BioPharm Holdings PLC

Maxim 1, Motherwell, United Kingdom, ML1 4WR

Key Executives

Name Title Year Born
Dr. Michael Leek M.B.A., Ph.D. Co-Founder & Exec. Chairman 1961
Mr. Bryan L. Kobel CEO & Director 1981
Ms. Angela Scott Co-Founder & COO 1964
Mr. Martin E. Thorp CFO & Director 1952
Mr. Christopher Camarra Exec. VP of Communications NA
Mr. Bryan L. Kobel CEO & Director 1979
Mr. Christopher Camarra Executive Vice President of Communications NA
Dr. Lauren Bor Ph.D. Head of Commercial Development Division NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.